Smurf2靶向EYA2对高糖诱导肾小球系膜细胞增殖和纤维化的影响

承德医学院学报 ›› 2025, Vol. 42 ›› Issue (5): 378-383.

Smurf2靶向EYA2对高糖诱导肾小球系膜细胞增殖和纤维化的影响

陈丽贞¹, 刘垠浩^1,*, 陈育青², 刘霏¹, 郭腾捷³

1.福建省漳州市中医院糖肾科,福建漳州 363000;
2.漳州卫生职业学院药学院,福建漳州 363000;
3.福建省漳州市中医院检验科,福建漳州 363000

收稿日期:2025-03-10 出版日期:2025-10-10 发布日期:2025-10-23
通讯作者: *
基金资助:
漳州市自然科学基金（ZZ2023J09）; 福建省自然科学基金（2024J011586）

Effect of Smurf2 Targeting EYA2 on Proliferation and Fibrosis of Glomerular Mesangial Cells Induced by High Glucose

CHEN Li-zhen¹, LIU Yin-hao^1,*, CHEN Yu-qing², LIU Fei¹, GUO Teng-jie³

1. Department of Diabetes Nephrology Zhangzhou Hospital of Traditional Chinese Medicine, Fujian Zhangzhou 363000, China;
2. School of Pharmacy Zhangzhou Health Vocational College, Zhangzhou, Fujian, 363000, China;
3. Department of Clinical Laboratory Zhangzhou Hospital of Traditional Chinese Medicine, Zhangzhou, Fujian, 363000, China

Received:2025-03-10 Online:2025-10-10 Published:2025-10-23

摘要/Abstract

摘要： 目的探究Smurf2通过靶向EYA2影响高糖诱导肾小球系膜细胞增殖和纤维化的分子机制。方法培养小鼠肾小球系膜细胞（GMCs）,将sh-Smurf2与sh-NC载体转染到高糖诱导的GMCs中,分组为：空白对照组（NG）、高糖处理组（HG）、高糖+sh-NC组（HG+sh-NC）、高糖+sh-Smurf2组（HG+sh-Smurf2）。CCK-8实验和EdU实验检测各组细胞增殖,蛋白印迹法（Western blot）检测各组细胞Fibronectin、Collagen I、α-SMA蛋白的表达;采用CO-IP实验检测Smurf2与EYA2的靶向互作关系,进一步采用sh-EYA2与sh-NC载体转染GMCs中进行回溯实验验证。结果与NG组相比,HG组细胞增殖显著上升,Fibronectin、Collagen I、α-SMA蛋白表达显著升高;与HG组相比,干扰Smurf2可以抑制细胞增殖,并抑制Fibronectin、Collagen I、α-SMA蛋白的表达。CO-IP结果显示Smurf2与EYA2存在靶向互作关系,且与HG+sh-Smurf2组相比,干扰EYA2可以促进细胞增殖,并促进Fibronectin、Collagen I、α-SMA蛋白的表达。结论干扰Smurf2可以通过上调EYA2抑制高糖诱导的GMCs过度增殖与纤维化。

关键词: 肾小球系膜细胞, Smurf2, EYA2, 增殖, 纤维化

Abstract: Objective To explore the molecular mechanism of Smurf2's effect on hyperglycemia-induced mesangial cell proliferation and fibrosis by targeting EYA2. Methods Mouse mesangial cells (GMCs) were cultured, and sh-Smurf2 and sh-NC vectors were transfected into GMCs induced by high glucose. Cell proliferation in blank control group (NG), high glucose treatment group (HG), high glucose + sh-NC group (HG + sh-NC), and high glucose + sh-Smurf2 group (HG + sh-Smurf2) were detected by CCK-8 and EdU. The expressions of Fibronectin, Collagen I and α-SMA proteins were detected by Western blot. CO-IP assay was employed to detect the targeting interaction between Smurf2 and EYA2, and then sh-EYA2 and sh-NC vectors were used to transfect GMCs for backtracking experiments. Results Compared with NG group, cell proliferation and protein expression of Fibronectin, Collagen I and α-SMA in HG group were significantly increased. Compared with HG group, interference with Smurf2 inhibited cell proliferation and the expression of Fibronectin, Collagen I and α-SMA proteins. CO-IP results showed a targeted interaction between Smurf2 and EYA2. Compared with HG + sh-Smurf2 group, interference with EYA2 promoted cell proliferation and the expression of Fibronectin, Collagen I and α-SMA proteins. Conclusion Interference with Smurf2 can inhibit hyperproliferation and fibrosis of GMCs induced by high glucose by upregulating EYA2.

Key words: glomerular mesangial cells, Smurf2, EYA2, proliferation, fibrosis

中图分类号:

R692

陈丽贞, 刘垠浩, 陈育青, 刘霏, 郭腾捷. Smurf2靶向EYA2对高糖诱导肾小球系膜细胞增殖和纤维化的影响[J]. 承德医学院学报, 2025, 42(5): 378-383.

CHEN Li-zhen, LIU Yin-hao, CHEN Yu-qing, LIU Fei, GUO Teng-jie. Effect of Smurf2 Targeting EYA2 on Proliferation and Fibrosis of Glomerular Mesangial Cells Induced by High Glucose[J]. Journal of Chengde Medical University, 2025, 42(5): 378-383.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://tougao.cdmc.edu.cn:8088/CN/

http://tougao.cdmc.edu.cn:8088/CN/Y2025/V42/I5/378

参考文献

[1] Dwivedi S, Sikarwar MS.Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies[J]. Horm Metab Res, 2025, 57(1): 7-17.
[2] Sun T, Guo Y, Su Y, et al.Molecular mechanisms of diabetic nephropathy: A narrative review[J]. Cell Biol Int, 2024, 48(9): 1240-1253.
[3] Luo Y, Zhang W, Qin G.Metabolomics in diabetic nephropathy: Unveiling novel biomarkers for diagnosis (Review)[J]. Mol Med Rep, 2024, 30(3): 156-168.
[4] Zhao DM, Zhong R, Wang XT, et al.Mitochondrial dysfunction in diabetic nephropathy: insights and therapeutic avenues from traditional Chinese medicine[J]. Front Endocrinol (Lausanne), 2024, 15(7): 1429420.
[5] Kaushik M, Kaushik A, Chaudhary J, et al.Terpenoids in Diabetic Nephropathy: Advances and Therapeutic Opportunities[J]. Endocr Metab Immune Disord Drug Targets, 2024, 24(1): 13-30.
[6] Li X, Zhang Y, Xing X, et al.Podocyte injury of diabetic nephropathy: Novel mechanism discovery and therapeutic prospects[J]. Biomed Pharmacother, 2023, 168(12): 115670.
[7] Tung CW, Hsu YC, Shih YH, et al.Glomerular mesangial cell and podocyte injuries in diabetic nephropathy[J]. Nephrology (Carlton), 2018, 23(4): 32-37.
[8] Hu S, Hang X, Wei Y, et al.Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review[J]. Cell Commun Signal, 2024, 22(1): 136-154.
[9] Naaman SC, Bakris GL.Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression[J]. Diabetes Care, 2023, 46(9): 1574-1586.
[10] Hu Q, Jiang L, Yan Q, et al.A natural products solution to diabetic nephropathy therapy[J]. Pharmacol Ther, 2023, 241(1): 108314.
[11] Tsai YC, Kuo MC, Hung WW, et al.Proximal tubule-derived exosomes contribute to mesangial cell injury in diabetic nephropathy via miR-92a-1-5p transfer[J]. Cell Commun Signal, 2023, 21(1): 10-23.
[12] Fang Z, Lee K, He JC.A central role for mesangial cells in the initiation of diabetic nephropathy[J]. Kidney Int, 2023, 104(5): 872-874.
[13] Deng L, Wu Z, Sun C, et al.Transcriptome analysis revealed SMURF2 as a prognostic biomarker for oral cancer[J]. J Appl Genet, 2025, 66(1): 155-170.
[14] Ren J, Yu L, Zhang Q, et al.AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase[J]. Virol Sin, 2024, 39(4): 632-644.
[15] Zhang W, Dai J, Hou G, et al.SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation[J]. Mol Cell, 2023, 83(23): 4352-4369.
[16] Jeon S, Jin H, Kim JM, et al.The miR-15b-Smurf2-HSP27 axis promotes pulmonary fibrosis[J]. J Biomed Sci, 2023, 30(1): 2-14.
[17] Guan G, Xie J, Dai Y, et al.TFPI2 suppresses the interaction of TGF-β2 pathway regulators to promote endothelial-mesenchymal transition in diabetic nephropathy[J]. J Biol Chem, 2022, 298(3): 101725.
[18] Kim D, Nam GY, Seo E, et al.Inhibition of ChREBP ubiquitination via the ROS/Akt-dependent downregulation of Smurf2 contributes to lysophosphatidic acid-induced fibrosis in renal mesangial cells[J]. J Biomed Sci, 2022, 29(1): 31-49.
[19] Ge X, Xi L, Wang Q, et al.Circular RNA Circ_0000064 promotes the proliferation and fibrosis of mesangial cells via miR-143 in diabetic nephropathy[J]. Gene, 2020, 758(10): 144952.
[20] Chen J, Ou Z, Gao T, et al.Ginkgolide B alleviates oxidative stress and ferroptosis by inhibiting GPX4 ubiquitination to improve diabetic nephropathy[J]. Biomed Pharmacother, 2022, 156(12): 113953.
[21] Li Y, Ren D, Shen Y, et al.Altered DNA methylation of TRIM13 in diabetic nephropathy suppresses mesangial collagen synthesis by promoting ubiquitination of CHOP[J]. EBioMedicine, 2020, 51(1): 102582.
[22] Xu Z, Diao Z, Liu R, et al.Molecular mechanism of smurf2 in regulating the expression of SnoN in diabetic nephropathy[J]. Mol Med Rep, 2017, 15(5): 2560-2566.
[23] Alderman C, Krueger A, Rossi J, et al.In Vitro Phosphatase Assays for the Eya2 Tyrosine Phosphatase[J]. Methods Mol Biol, 2024, (2743): 285-300.
[24] Wolin AR, Vincent MY, Hotz T, et al.EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression[J]. Neuro Oncol, 2023, 25(12): 2287-2301.
[25] Awwad SW, Darawshe MM, Machour FE, et al.Recruitment of RBM6 to DNA Double-Strand Breaks Fosters Homologous Recombination Repair[J]. Mol Cell Biol, 2023, 43(3): 130-142.
[26] Li Z, Qiu R, Qiu X, et al.EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN[J]. Oncotarget, 2017, 8(67): 110837-110848.
[27] Xu H, Jiao Y, Yi M, et al.EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival[J]. Front Oncol, 2019, 9(1): 26-38.